2010 guide to psychiatric drug interactions

Sheldon H. Preskorn, David Flockhart

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Drug-drug interactions (DDIs) are a concern for the prescriber because they have the potential for causing untoward outcomes for everyone involved: morbidity for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. Based on the 2004 Health and Human Services report, 7% of Americans >18 years of age and >20% of Americans >65 years of age had taken ≥5 prescription medications in the week preceding the survey. Patients on psychiatric medications, such as antidepressants, are on more medication than patients not on psychiatric medications. Prescribers should appreciate that medications interact not on the basis of their therapeutic use, but on the basis of their pharmacodynamics and pharmacokinetics. For this reason, the prescriber of psychiatric medications must consider all of the medications the patient is taking. Similar to the 2006 version, this educational review focuses on neuropsychiatric medications but also covers all other drugs to the extent that they interact with psychiatric medications. It emphasizes the role of pharmacologic principles to guide the safe and effective use of multiple medications when such use is necessary. Consistent with these principles, this review presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.

Original languageEnglish
Pages (from-to)45-74
Number of pages30
JournalPrimary Psychiatry
Volume16
Issue number12
StatePublished - Dec 2009

Fingerprint

Drug Interactions
Psychiatry
Pharmaceutical Preparations
Pharmacokinetics
Therapeutic Uses
Antidepressive Agents
Health Services
Prescriptions
Morbidity
Delivery of Health Care
Costs and Cost Analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Preskorn, S. H., & Flockhart, D. (2009). 2010 guide to psychiatric drug interactions. Primary Psychiatry, 16(12), 45-74.

2010 guide to psychiatric drug interactions. / Preskorn, Sheldon H.; Flockhart, David.

In: Primary Psychiatry, Vol. 16, No. 12, 12.2009, p. 45-74.

Research output: Contribution to journalArticle

Preskorn, SH & Flockhart, D 2009, '2010 guide to psychiatric drug interactions', Primary Psychiatry, vol. 16, no. 12, pp. 45-74.
Preskorn SH, Flockhart D. 2010 guide to psychiatric drug interactions. Primary Psychiatry. 2009 Dec;16(12):45-74.
Preskorn, Sheldon H. ; Flockhart, David. / 2010 guide to psychiatric drug interactions. In: Primary Psychiatry. 2009 ; Vol. 16, No. 12. pp. 45-74.
@article{5ea9a7e2a5734956bf32a465919ca696,
title = "2010 guide to psychiatric drug interactions",
abstract = "Drug-drug interactions (DDIs) are a concern for the prescriber because they have the potential for causing untoward outcomes for everyone involved: morbidity for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. Based on the 2004 Health and Human Services report, 7{\%} of Americans >18 years of age and >20{\%} of Americans >65 years of age had taken ≥5 prescription medications in the week preceding the survey. Patients on psychiatric medications, such as antidepressants, are on more medication than patients not on psychiatric medications. Prescribers should appreciate that medications interact not on the basis of their therapeutic use, but on the basis of their pharmacodynamics and pharmacokinetics. For this reason, the prescriber of psychiatric medications must consider all of the medications the patient is taking. Similar to the 2006 version, this educational review focuses on neuropsychiatric medications but also covers all other drugs to the extent that they interact with psychiatric medications. It emphasizes the role of pharmacologic principles to guide the safe and effective use of multiple medications when such use is necessary. Consistent with these principles, this review presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.",
author = "Preskorn, {Sheldon H.} and David Flockhart",
year = "2009",
month = "12",
language = "English",
volume = "16",
pages = "45--74",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "12",

}

TY - JOUR

T1 - 2010 guide to psychiatric drug interactions

AU - Preskorn, Sheldon H.

AU - Flockhart, David

PY - 2009/12

Y1 - 2009/12

N2 - Drug-drug interactions (DDIs) are a concern for the prescriber because they have the potential for causing untoward outcomes for everyone involved: morbidity for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. Based on the 2004 Health and Human Services report, 7% of Americans >18 years of age and >20% of Americans >65 years of age had taken ≥5 prescription medications in the week preceding the survey. Patients on psychiatric medications, such as antidepressants, are on more medication than patients not on psychiatric medications. Prescribers should appreciate that medications interact not on the basis of their therapeutic use, but on the basis of their pharmacodynamics and pharmacokinetics. For this reason, the prescriber of psychiatric medications must consider all of the medications the patient is taking. Similar to the 2006 version, this educational review focuses on neuropsychiatric medications but also covers all other drugs to the extent that they interact with psychiatric medications. It emphasizes the role of pharmacologic principles to guide the safe and effective use of multiple medications when such use is necessary. Consistent with these principles, this review presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.

AB - Drug-drug interactions (DDIs) are a concern for the prescriber because they have the potential for causing untoward outcomes for everyone involved: morbidity for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. Based on the 2004 Health and Human Services report, 7% of Americans >18 years of age and >20% of Americans >65 years of age had taken ≥5 prescription medications in the week preceding the survey. Patients on psychiatric medications, such as antidepressants, are on more medication than patients not on psychiatric medications. Prescribers should appreciate that medications interact not on the basis of their therapeutic use, but on the basis of their pharmacodynamics and pharmacokinetics. For this reason, the prescriber of psychiatric medications must consider all of the medications the patient is taking. Similar to the 2006 version, this educational review focuses on neuropsychiatric medications but also covers all other drugs to the extent that they interact with psychiatric medications. It emphasizes the role of pharmacologic principles to guide the safe and effective use of multiple medications when such use is necessary. Consistent with these principles, this review presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.

UR - http://www.scopus.com/inward/record.url?scp=75349110222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75349110222&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:75349110222

VL - 16

SP - 45

EP - 74

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 12

ER -